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Purpose: The approach to the use of generic antiepileptic drugs has recently evolved from 
major concern to general acceptance, but the evidence related specifically to the safety of 
switching from brand-name to generic levetiracetam (LEV) is scarce. The aim of the study was 
to assess the risk of increased frequency of seizures or other adverse events after replacement 
of a brand-name LEV with a generic one.
Patients and methods: This retrospective analysis included 159 patients treated with LEV 
in a tertiary outpatient epilepsy clinic. We included all patients diagnosed with epilepsy who 
were treated with LEV as at March 1, 2013. Most patients were forced to switch to the generic 
LEV because of the sudden rise in cost of the branded LEV. We recorded data on age, sex, age 
at onset of epilepsy, type of epilepsy, and its treatment. We analyzed data from one visit before 
potential switching and from two visits after the potential switching. The interval between 
visits was typically 3 months. We registered an increase in the frequency of seizures and in the 
occurrence of adverse events.
Results: Among 151 subjects who switched to generic LEV after March 1, 2013, increased 
frequency of seizures was noted in 9 patients (6%) during the first follow-up visit. Patients with 
increased frequency of seizures did not differ from other patients regarding sex, age, age at the 
onset of epilepsy, and the median dose of LEV before switching or the median duration of treat-
ment with LEV before switching. Two patients returned to brand-name LEV. Adverse events 
were noted in six other patients (4%) and included somnolence, irritability, or dizziness.
Conclusion: Switching from brand-name to generic LEV is generally safe.
Keywords: levetiracetam, generic, branded, epilepsy, switching, adverse event
Introduction
At present, generic formulations of all conventional and most of the newer antiepileptic 
drugs (AEDs) are available. The use of generic AEDs substantially reduces the costs of 
treatment and is therefore encouraged by regulatory bodies (such as US Food and Drug 
Administration [FDA]) and health insurance systems. On the other hand, switching 
from brand-name to generic formulations has raised concerns among physicians and 
patients regarding loss of seizure control and occurrence of adverse events.
The approach to the use of generic AEDs has changed over the recent years. 
Initially, most professional societies, including American Academy of Neurology,1 
Italian League Against Epilepsy,2 American Epilepsy Society,3 and National Institute 
for Health and Clinical Excellence4 issued statements against compulsory switching 
that were based mostly on the results of observational studies and case series. Over 
the years, a growing body of evidence, including a very recent randomized study,5 
suggested reasonable safety of the switching and led to the reversal of the opinions and 
statements released recently by professional bodies. In 2016, the American Epilepsy 
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Society acknowledged that drug formulation substitution 
with FDA-approved generic products reduces cost without 
compromising efficacy.6
A majority of studies that analyzed switch from the 
brand-name to generic AEDs included patients taking various 
AEDs7–11 or lamotrigine.12 The risk related specifically to the 
switching from branded to generic levetiracetam (LEV) was 
assessed only in two studies with discordant results.13,14 Thus, 
the evidence is scarce and justifies further evaluation.
The pharmaceutical policy in Poland includes reimburse-
ment of some medications, including AEDs. Every 2 months, 
a Ministry of Health issues the list of the medications 
(brand-name and generic ones) that are refunded either by 
specific proportion (eg, 50%) or to the specified price. On 
March 1, 2013, the price of the brand-name LEV increased 
by about 20–30 times (depending on the formulation) and 
most patients were forced to switch to generic formulations 
because of financial issues (the price of the generic LEV 
remained at the same level). Therefore, we planned to analyze 
the consequences of such switching among epileptic patients 
treated in the tertiary epilepsy outpatient clinic. Our aim was 
to assess the risk of increased frequency of seizures or other 
adverse events after replacement of the branded LEV with 
the generic one.
Patients and methods
Patients
This study was a retrospective analysis of patients who were 
treated with LEV in the tertiary outpatient epilepsy clinic at 
the Department of Neurology, Hospital University of Krakow, 
Poland. We included all patients diagnosed with epilepsy who 
were treated with LEV on March 1, 2013. This date was a 
turning point in the management of those patients because 
a vast majority of them were expected to switch from the 
brand-name to the generic LEV due to a substantial increase 
in the price of brand-name LEV (see Introduction).
The protocol of the study followed the principles included 
in the Declaration of Helsinki and was approved by the Bio-
ethical Committee of the Jagiellonian University of Krakow. 
Patients’ consent to review their medical records was not 
required by the committee because the only person allowed 
to do so (M.B.) was the physician who took care of all those 
patients. Two other authors who analyzed and interpreted 
data used the electronic database without details that would 
enable patient identification.
Methods
Using the electronic database, we recorded data on age, sex, 
age at onset of epilepsy, and treatment of epilepsy (mono- or 
polytherapy, AEDs used, and the dose and formulation of 
LEV). The type of epilepsy was retrospectively classified 
with the terminology used in a recent International League 
Against Epilepsy position paper on the classification of epi-
lepsies (generalized, focal, combined generalized, and focal 
or unknown) to facilitate future comparisons.15 We analyzed 
data from one visit before potential switching and from two 
visits after the potential switching. The interval between visits 
was typically 3 months. We noted the baseline frequency of 
seizures and its potential change after switching. We also 
registered potential adverse events.
Qualitative variables were characterized with numbers 
and percentages. Quantitative variables were described with 
the use of a median with interquartile range (IQR) due to the 
skewed distribution. Chi-square test (or Fisher exact test, 
where appropriate) was used to assess the significance of 
the differences between the qualitative data. Mann–Whitney 
U-test was used to assess differences between quantitative 
variables. A P-value of ,0.05 was considered statistically 
significant. All the analyses were performed using Statistica 
v. 12.5 (StatSoft Inc., Tulsa, OK, USA).
Results
Table 1 provides the clinical characteristics of 159 patients 
who were treated with LEV on March 1, 2013. After this 
date, 151 subjects switched to the generic LEV within about 
1 month (when they ran out of the brand-name medication). 
Their clinical characteristics are summarized in Table 2. One 
hundred and nine patients (72.2%) received generic LEV 
produced by TEVA (Levetiracetam TEVA) and 42 others 
(27.8%) used generic LEV produced by Adamed (Vetira). 
Table 1 clinical characteristics of studied patients treated with 
levetiracetam
Variable N=159a
age (years); median (iQr) 34 (27–42)
age at onset of epilepsy (years); median (iQr) 14 (6–20)
sex (women) 91 (57.2%)
Type of epilepsy
generalized 19 (12.0%)
Focal 132 (83.0%)
Unknown 8 (5.0%)
Daily dose of leV (mg); median (iQr) 2,000 (1,250–3,000)
number of aeDs used
1 15 (9.4%)
2 90 (56.7%)
3 50 (31.4%)
Unknown 4 (2.5%)
Duration of treatment with leV (years); 
median (iQr)
3 (2–4)
Note: aOne patient used leV in solution, the others used tablets.
Abbreviations: aeD, antiepileptic drug; iQr, interquartile range; leV, 
levetiracetam.
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After switching, patients used the same formulation of LEV 
(tablets), the same dose per tablet, and the same daily dose.
Other AEDs most commonly used by the patients treated 
with LEV and one another medication included valproic 
acid (30 patients), carbamazepine (21 patients), lamotrigine 
(13 patients), and oxcarbazepine (13 patients). Patients 
treated with three AEDs most commonly used a combination 
of LEV with valproic acid and carbamazepine (11 patients), 
valproic acid and topiramate (9 patients), valproic acid and 
lamotrigine (7 patients), or carbamazepine and lamotrigine 
(4 patients).
The clinical characteristics of eight other patients who 
continued treatment with the brand-name LEV is shown in 
Table 2. The only variable that differed significantly between 
those patients and those who switched to generic LEV was 
the longer duration of treatment with LEV among patients 
who did not switch.
The increased frequency of seizures (.30% of the 
baseline frequency) was noted in nine patients (6%) during 
the first follow-up visit after switching. In seven patients, 
the dose of the generic LEV was subsequently increased by 
25% with the resulting decrease of seizure frequency. In two 
other patients, it was necessary to return to the brand-name 
LEV, and the frequency of seizures returned to the baseline 
in both of them.
The subgroup of nine patients with increased frequency 
of seizures comprised four women and five men; all patients 
had focal epilepsy and all received more than one AED 
for their epilepsy (seven patients took two AEDs and two 
patients were treated with three AEDs). Medications used 
in polytherapy of epilepsy in those subjects included oxcar-
bazepine (2 patients), carbamazepine (2), valproic acid (1), 
gabapentin (1), lamotrigine (1), lamotrigine and valproic 
acid (1), and clobazam and valproic acid (1). Patients in this 
subgroup reported no adverse events other than increased 
frequency of seizures.
The adverse events were noted in six other patients 
(4.0%) at the first follow-up visit after switching and included 
somnolence (2 patients), irritability (2), or somnolence and 
dizziness (2). All adverse events disappeared at the second 
follow-up visit and did not lead to the modification of 
treatment.
The group of patients with increased frequency of seizures 
did not differ from patients with unchanged frequency of 
seizures in terms of age (36 [34–51] vs 33 [28–42] years, 
respectively; P=0.15), age at the onset of epilepsy (16 [5–43] 
vs 14 [6–20] years, respectively; P=0.55), median dose 
of LEV before switching (2,000 [1,500–3,000] vs 2,000 
[1,000–3,000] mg, respectively; P=0.60) and the median 
duration of treatment with LEV before switching (4 [3–4] 
vs 3 [2–4] years, respectively; P=0.17).
We did not observe any change in seizure frequency or 
additional adverse events in eight patients who continued 
treatment with the brand-name LEV.
Discussion
This retrospective analysis of epileptic patients who switched 
from the brand-name LEV to generic LEV suggests that such 
Table 2 comparison of clinical characteristics of patients treated with the brand-name leV who were switched to generic leV or 
continued treatment with the brand-name leV
Variable Patients who switched 
to generic LEV (n=151)
Patients who continued treatment 
with the brand-name LEV (n=8)
age (years); median (iQr) 34 (28–42) 30.5 (20.5–44.5)
age at onset of epilepsy (years); median (iQr) 14 (6–20) 8.5 (3–15.5)
sex (women) 88 (58.3%) 3/8
Type of epilepsy
generalized 19 (12.6%) 0
Focal 125 (82.8%) 6/8
Unknown 7 (4.6%) 2/8
Duration of treatment with leV (years); median (iQr) 3 (2–4) 5 (4–5)a
Daily dose of leV (mg); median (iQr) 2,000 (1,000–3,000) 2,500 (1,250–3,000)
increased frequency of seizures 9 (6.0%) 0
adverse reactions 6 (4.0%) 0
number of aeDs used
1 15 (9.9%) 0
2 85 (56.3%) 5/8
3 49 (32.5%) 2/8
na 2 (1.3%) 1/8
Notes: aP,0.01 for the difference in duration of treatment with LEV; other differences were not significant.
Abbreviations: aeD, antiepileptic drug; iQr, interquartile range; leV, levetiracetam; na, not available.
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a change is generally safe. Increased frequency of seizures 
was noted only in nine patients (6%) and only two of them 
required switchback to the brand-name LEV. Adverse events 
were noted in 4% of patients; they were mild, transient, and 
did not lead to discontinuation or switchback.
Various AEDs may exhibit different effects when 
switched from the brand-name to generic formulations. Our 
study is only the third to report findings related specifically 
to LEV; thus, the evidence is still equivocal. Our findings 
are at variance with a similar retrospective observation pub-
lished by Chaluvadi et al.13 These authors observed increased 
frequency of seizures in 19.3% of patients (three times more 
often than we did). Also, as much as 42.8% of their patients 
were switched back to the brand-name LEV, which is in 
sharp contrast to two patients who required such a change 
in our sample. The frequency of adverse events was similar 
in those two studies (3.3% vs 4.0%).
These discordant results may be partially explained by 
the different characteristics of populations studied. More than 
90% of our patients had drug-resistant epilepsy and were 
treated with multiple medications. It stems from the fact that 
before March 1, 2013 brand-name (and generic) LEV was 
reimbursed only for patients with drug-resistant epilepsy. 
Also, the tertiary outpatient clinic had a disproportionately 
high proportion of patients on polytherapy. The study sample 
analyzed by Chaluvadi et al comprised 35.5% of patients on 
monotherapy. It may be argued that patients on monotherapy 
are more prone to increased frequency of seizures, as by defi-
nition, there is only one medication to control seizures.
On the other hand, our results are consistent with the 
second and more recent study related to switching from 
brand-name to generic LEV.14 These authors analyzed 
59 patients and did not observe increased frequency of 
seizures after switching from brand-name LEV to generic 
during a 6-month follow-up. In their study, two patients 
(3.4%) restarted the therapy with the branded LEV because 
of increased frequency of seizures.
Increased frequency of seizures in a small percentage of 
patients who switched from brand-name to generic LEV can 
be attributed to several mechanisms.
The early observational studies pointed to the increased 
frequency of seizures, occurrence of adverse events, and actual 
increase of costs when brand-name AEDs were switched to 
the generic ones.7,11,16,17 Consequently, some authors argued 
that the requirements related to the bioequivalence of AEDs 
were too permissive, especially for medications with narrow 
therapeutic indices.18 Subsequent studies, however, led to 
an important change in the paradigm regarding the use of 
generic AEDs. Ting et al19 confirmed bioequivalence of 
the brand-name and generic lamotrigine; Privitera et al5 
showed bioequivalence of the several generic formulations 
of lamotrigine. Both studies did not reveal any change in 
frequency of seizures or incidence of adverse events because 
of the switching between various formulations of lamotrigine. 
Similar observations were made in population-based studies 
on lamotrigine13,20 or various AEDs.21 Finally, Davit et al22 
reviewed 2070 clinical bioequivalence studies of oral generic 
drugs approved by the FDA over 12 years and confirmed the 
validity of the current criteria used for the approval of generic 
medications. It seems, therefore, unlikely that the differences 
in bioequivalence might explain the increased frequency of 
seizures after switching.
Such increased frequency of seizures in some patients 
can be related to the natural course of epileptic disorder in 
which the periods of better or worse control of seizure can 
interlace.
Also, some authors suggest that the refilling process itself 
may be associated with the increased frequency of seizures 
irrespective of whether refilling involved brand-name or 
generic AED10 or different generic AEDs.21 The explana-
tions for this phenomenon may include minor but important 
changes in bioavailability or lapses in pharmacotherapy 
continuity related to the refilling process.
We believe that some additional psychological aspects 
associated with the process of switching can contribute to 
the increased frequency of seizures in a small minority of 
patients. Previous concerns of prescribing physicians, based 
on relevant statements and warnings, might result in more 
detailed explanations and precautions that would in fact make 
patients less reassured. At present, when the bioequivalence 
of brand-name and generic AED is supported by robust 
evidence, physicians and patients are less prone to the stress 
related to the process of switching, which may act as a self-
fulfilling prophecy. In our study, all patients were managed 
by the single physician who provided consistent and identical 
information on switching to all subjects.
We acknowledge some limitations in our study, mainly its 
retrospective design and relatively small sample size (n=159). 
The small number of patients who did not switch and the 
small number of those who experienced adverse events after 
switching make meaningful comparisons difficult. On the 
other hand, two other published studies related specifically 
to LEV and discussed earlier included 59 and 260 patients. 
We did not assess the serum levels of LEV before and after 
switching. At the time of the study, measurement of LEV 
levels was not available at our laboratory.
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Conclusion
The switching from brand-name to generic LEV is generally 
safe. The proportion of patients who experienced increased 
frequency of seizures was small (6%), as was the number of 
patients who returned to the brand-name LEV after a 6-month 
follow-up (1.3%).
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